{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:41:31Z","timestamp":1790880091961,"version":"4.1.0"},"reference-count":25,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Student or Recent Graduate Research Project bursary from the Quebec Association of Genetic Counsellors"},{"name":"Department of Human Genetics at McGill University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Up to 20% of women diagnosed with tubo-ovarian carcinoma carry a germline pathogenic variant in a cancer-predisposing gene (e.g., BRCA1\/BRCA2). Identifying these variants can help to inform eligibility for therapies, guide surveillance and prevention of new primary cancers, and assess risk to family members. The Gynecologic Oncology-Initiated Genetic Testing Model (GOIGT) was initiated at the McGill University Health Centre (MUHC) to streamline universal germline genetic testing for this population, while addressing the limited resources in the public healthcare system. This study aimed to evaluate the patient experience of participating in this model. Methods: Study participants were patients diagnosed with high-grade non-mucinous epithelial tubo-ovarian cancer who underwent genetic testing through the GOIGT model between 1 January 2017 and 31 December 2020. Eligible participants completed the retrospective questionnaires at least one month after result disclosure. Results: A total of 126 patients were tested through the GOIGT model during the study period, of which 56 were invited to participate. Thirty-four participants returned the study questionnaire. Overall, participants did not report decision regret following the genetic testing and were satisfied with the GOIGT model. Participants reported low levels of uncertainty and distress related to the implications of their test results for themselves and their family members. Conclusions: The results of this study support the continued implementation of mainstreamed genetic testing models for women with high-grade non-mucinous tubo-ovarian cancer. Further studies are required to compare experiences for patients with different genetic test results.<\/jats:p>","DOI":"10.3390\/curroncol29050288","type":"journal-article","created":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T09:48:22Z","timestamp":1652608102000},"page":"3565-3575","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Patient Experience with a Gynecologic Oncology-Initiated Genetic Testing Model for Women with Tubo-Ovarian Cancer"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1592-9467","authenticated-orcid":false,"given":"Michaela Bercovitch","family":"Sadinsky","sequence":"first","affiliation":[{"name":"Department of Human Genetics, McGill University, Montreal, QC H3A0C7, Canada"},{"name":"Division of Medical Genetics, Jewish General Hospital, McGill University, Montreal, QC H3T1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Power","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, McGill University Health Centre, Montreal, QC H4A3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enza","family":"Ambrosio","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, McGill University Health Centre, Montreal, QC H4A3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Palma","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, McGill University, Montreal, QC H3A0C7, Canada"},{"name":"Division of Medical Genetics, McGill University Health Centre, Montreal, QC H4A3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zeng","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, McGill University Health Centre, Montreal, QC H4A3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Foulkes","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, McGill University, Montreal, QC H3A0C7, Canada"},{"name":"Division of Medical Genetics, Jewish General Hospital, McGill University, Montreal, QC H3T1E2, Canada"},{"name":"Division of Medical Genetics, McGill University Health Centre, Montreal, QC H4A3J1, Canada"},{"name":"Department of Specialized Medicine, Lady David Institute, Jewish General Hospital, McGill University, Montreal, QC H3T1E2, Canada"},{"name":"Cancer Research Program, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H4A3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, McGill University, Montreal, QC H3A0C7, Canada"},{"name":"Division of Medical Genetics, McGill University Health Centre, Montreal, QC H4A3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,15]]},"reference":[{"key":"ref_1","unstructured":"Chen, L.-M., Berek, J., and Goff, B. (2021, April 15). Epithelial Carcinoma of the Ovary, Fallopian Tube, and Peritoneum: Clinical Features and Diagnosis. Uptodate. Available online: https:\/\/www.uptodate.com\/contents\/epithelial-carcinoma-of-the-ovary-fallopian-tube-and-peritoneum-clinical-features-and-diagnosis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.18632\/oncotarget.6834","article-title":"BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing","volume":"7","author":"Mafficini","year":"2016","journal-title":"Oncotarget"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited Mutations in Women with Ovarian Carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3747\/co.24.3828","article-title":"Coming of Age in Canada: A Study of Population-Based Genetic Testing for Breast and Ovarian Cancer","volume":"24","author":"Akbari","year":"2017","journal-title":"Curr. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients","volume":"37","author":"Kurian","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.critrevonc.2016.02.014","article-title":"Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response","volume":"101","author":"Cacheux","year":"2016","journal-title":"Crit. Rev. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/jmedgenet-2018-105472","article-title":"Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: A Canadian multisociety roadmap","volume":"55","author":"McCuaig","year":"2018","journal-title":"J. Med. Genet."},{"key":"ref_9","unstructured":"SGOC (2021, March 25). No Woman Left Behind: Toward a Pan-Canadian Strategy for Universal BRCA Testing in Ovarian Cancer [Position Statement]. Available online: https:\/\/g-o-c.org\/wp-content\/uploads\/2015\/01\/17PosStmt_NWLB_Jan31_FINAL-EN.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/IGC.0000000000000907","article-title":"Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario","volume":"27","author":"McGee","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1136\/ijgc-2020-001261","article-title":"BRCA testing in women with high-grade serous ovarian cancer: Gynecologic oncologist-initiated testing compared with genetics referral","volume":"30","author":"Piedimonte","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29506","DOI":"10.1038\/srep29506","article-title":"Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients","volume":"6","author":"George","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ygyno.2017.07.141","article-title":"Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care","volume":"147","author":"Senter","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygyno.2017.01.030","article-title":"Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics","volume":"145","author":"Kentwell","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/jmedgenet-2017-105140","article-title":"Mainstreamed genetic testing for women with ovarian cancer: First-year experience","volume":"56","author":"Rahman","year":"2019","journal-title":"J. Med. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10897-018-0261-5","article-title":"Patients\u2019 Views of Treatment-Focused Genetic Testing (TFGT): Some Lessons for the Mainstreaming of BRCA1 and BRCA2 Testing","volume":"27","author":"Wright","year":"2018","journal-title":"J. Genet. Couns."},{"key":"ref_17","first-page":"133","article-title":"Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway. Fam","volume":"19","author":"Grindedal","year":"2020","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3390\/curroncol28020138","article-title":"A Comparison of Patient-Reported Outcomes Following Consent for Genetic Testing Using an Oncologist- or Genetic Counselor-Mediated Model of Care","volume":"28","author":"McCuaig","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/ijgc-2019-000630","article-title":"Mainstreamed genetic testing in ovarian cancer: Patient experience of the testing process","volume":"30","author":"McLeavy","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1200\/JCO.2017.76.2781","article-title":"Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer","volume":"36","author":"Colombo","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1470-2045(11)70333-3","article-title":"Assessment of symptomatic women for early diagnosis of ovarian cancer: Results from the prospective DOvE pilot project","volume":"13","author":"Gilbert","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1037\/0278-6133.21.6.564","article-title":"A brief assessment of concerns associated with genetic testing for cancer: The multidimensional impact of cancer risk assessment (MICRA) questionnaire","volume":"21","author":"Cella","year":"2002","journal-title":"Health Psychol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/0272989X03256005","article-title":"Validation of a Decision Regret Scale","volume":"23","author":"Brehaut","year":"2003","journal-title":"Med. Decis. Mak."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/jmedgenet-2016-103902","article-title":"New paradigms forBRCA1\/BRCA2testing in women with ovarian cancer: Results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study","volume":"53","author":"Plaskocinska","year":"2016","journal-title":"J. Med. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/0272989X16636113","article-title":"Extent and Predictors of Decision Regret about Health Care Decisions","volume":"36","author":"Menear","year":"2016","journal-title":"Med. Decis. Mak."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/5\/288\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:11:02Z","timestamp":1760137862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/5\/288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,15]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["curroncol29050288"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29050288","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,15]]}}}